Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Konstantin Schlick, Florian Hohla, Frank Hamacher, Hubert Hackl, Clemens Hufnagl, Steiner Markus, Teresa Magnes, Simon Peter Gampenrieder, Thomas Melchardt, Stefan Stättner, Cornelia Hauser-Kronberger, Richard Greil, Gabriel Rinnerthaler
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2021-02-01
Serie:	Future Science OA
Soggetti:	FOLFIRINOX gemcitabine miRNA pancreatic cancer
Accesso online:	https://www.future-science.com/doi/10.2144/fsoa-2020-0128
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!